

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Issued Patent of:	Kang et al.	Patent No.:	7,867,730
Application Serial No.:	10/587,956	Issued:	11-Jan-2011
Filed:	05-Oct-2007		
Entitled:	HANSENULA POLYMORPHA GENE CODING FOR ALPHA 1,6-MANNOSYLTRANSFERASE AND PROCESS FOR THE PRODUCTION OF RECOMBINANT GLYCOPROTEINS WITH HANSENULA POLYMORPHA MUTANT STRAIN DEFICIENT IN THE SAME GENE		

**REQUEST FOR CORRECTION OF PATENT FOR U.S. PATENT AND
TRADEMARK OFFICE MISTAKE UNDER 37 CFR § 1.322**

EFS WEB FILED

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. § 1.8	
I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being transmitted to the United States Patent and Trademark Office transmitted via the Office electronic filing system in accordance with 37 C.F.R. §1.6(a)(4).	
Dated: <u>March 4, 2011</u>	By: <u>/Kristen Heck/</u> Kristen Heck

Dear Sir:

Applicant requests pursuant to 37 CFR 1.322 the Commissioner to Issue a Certificate of Correction for the following U.S. Patent and Trademark Office Mistakes in the above referenced Issued Patent:

Applicant submits herewith U.S. Patent and Trademark Office Form PTO/SB/44, Certificate of Correction.

On the Title page, at (75), please insert a hyphen to inventor Joo-Hyung Heo's name. Applicant submits herewith a copy of the Assignment document recorded on October 5, 2007, showing therein the inventors name with the hyphen.

IN THE CLAIMS:

CLAIM 4 reads: "A recombinant vector comprising a nucleic acid molecule ..."

CLAIM 8 reads: "...wherein the recombinant glycoprotein lacks further sugar-chain synthesis of Man8 on N-linked glycosylation."

HOWEVER, IT SHOULD READ:

CLAIM 4: "A recombinant vector comprising the nucleic acid molecule..."

CLAIM 8: "...wherein said recombinant glycoprotein further lacks sugar-chain synthesis of Man8 on N-linked glycosylation."

Applicant believes no fee is due for the Issuance of the Certificate of Correction. The Commissioner is hereby authorized to charge Deposit Account No.: 50-4302, referencing Attorney Dkt. No.: ***HANOL - 13037*** if any fees are found to be due with this request.

Respectfully,

Date: March 4, 2011

/Tanya A. Arenson/
Tanya A. Arenson
Registration No. 47,391

Casimir Jones, S.C.
2275 Deming Way, Suite 310
Middleton, WI 53562
(608) 662-1277

ASSIGNMENT

WHEREAS, WE, Hyun-As Kang, Moo-Woong Kim, Sang-Ki Rhee & Joo-Hyung Heo, hereinafter referred to as "ASSIGNOR," have invented certain new and useful improvements as described and set forth in the below-identified application for United States Letters Patent:

Title of Invention: **A Novel Hansenula Polymorpha Gene Coding for Alpha 1,6-Mannosyltransferase and Process for the Production of Recombinant Glycoproteins with Hansenula Polymorpha Mutant Strain Deficient in the Same**

Filing Date: **07/31/2006** Serial No.: **10/587,956**

WHEREAS, Korea Research Institute of Biosciences and Biotechnology, Inc, a Republic of Korea corporation having a place of business at 52 Eoeun-dong, Yuseong-gu, Daejeon, Republic of Korea 305-333 hereinafter referred to as "ASSIGNEE," is desirous of acquiring the entire right, title and interest in said invention and application and in any Letters Patent which may be granted on the same;

NOW THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that, for and in consideration of employee and/or collaboration agreements between the ASSIGNOR and the ASSIGNEE, and other good and valuable consideration, receipt of which is hereby acknowledged, ASSIGNOR has sold, assigned and transferred, and by these presents does sell, assign and transfer unto said ASSIGNEE, and ASSIGNEE's successors and assigns, all right, title and interest in and to said invention, said application for United States Letters Patent, and any Letters Patent which may hereafter be granted on the same in the United States and all countries throughout the world, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, or prolongations or extensions thereof, said interest to be held and enjoyed by said ASSIGNEE as fully and exclusively as it would have been held and enjoyed by said ASSIGNOR had this assignment and transfer not been made, to the full extent and term of any Letters Patent.

ASSIGNOR further agrees that ASSIGNOR will, without charge to said ASSIGNEE, but at ASSIGNEE's expense, cooperate with ASSIGNEE in the prosecution of said application and/or applications; execute, verify, acknowledge, and deliver all such further papers, including applications for Letters Patent and for the reissue thereof, and instruments of assignment and transfer thereof; and perform such other acts as ASSIGNEE lawfully may request, to obtain or maintain Letters Patent for said invention and improvement in any and all countries, and to vest title thereto in said ASSIGNEE, or ASSIGNEE's successors and assigns.

IN TESTIMONY WHEREOF, ASSIGNOR has hereunto signed ASSIGNOR's name to this Assignment on the date indicated below.

<u>Hyun-As Kang</u>	<u>Oct 5, 2007</u>	<u>M. W. Kim</u>	<u>Oct 5, 2007</u>
Hyun-As Kang	Date	Moo-Woong Kim	Date
<u>Sang-Ki Rhee</u>	<u>Oct 5, 2007</u>	<u>Joo-Hyung Heo</u>	<u>Oct 5, 2007</u>
Sang-Ki Rhee	Date	Joo-Hyung Heo	Date

STATE OF)
COUNTY OF) ss.

On this 5th day of October, in the year of 2007, before me, the undersigned Notary Public or Witness, personally appeared the above-named ASSIGNOR, known to me (or proven to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are subscribed to the within instrument, and acknowledged that he/she/they executed the same.

SEAL

CHO SUN YOUNG
NOTARY PUBLIC or WITNESS
MY COMMISSION EXPIRES: April 4, 2008

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 7,867,730

APPLICATION NO.: 10/587,956

ISSUE DATE : January 11, 2011

INVENTOR(S) : Kang, et al

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title page, at (75), please insert a hyphen to inventor Joo-Hyung Heo's name.

The CLAIMS in the patent reads:

CLAIM 4: "A recombinant vector comprising a nucleic acid molecule ..."

CLAIM 8: "...wherein the recombinant glycoprotein lacks further sugar-chain synthesis of Man8 on N-linked glycosylation."

HOWEVER, IT SHOULD READ:

CLAIM 4: "A recombinant vector comprising the nucleic acid molecule..."

CLAIM 8: "...wherein said recombinant glycoprotein further lacks sugar-chain synthesis of Man8 on N-linked glycosylation."

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Casimir Jones, S.C.
2275 Deming Way, Suite 310
Middleton, WI 53562

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.